CD274 and cancer: Emerging immunotherapy, including anti-CTLA4 [45], anti-LAG3 [46], anti-PD-1, and anti-PD-L1 antibodies [47], has been proven to be efficacious and increased the survival rate of patients with several advanced cancers, including metastatic osteosarcoma patients [48].